香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 股東特別大會通告 茲通告山東威高集團醫用高分子製品股份有限公司（「本公司」）謹訂於二零 二五年十月十七日（星期五）上午九時正假座中國山東省威海火炬高技術產業 開發區威高路1號二樓舉行股東特別大會（「股東特別大會」），以審議並酌情通 過下列各項決議案： 除另有界定者外，本通告所用詞彙與本公司日期為二零二五年十月二日之通函 （「通函」）所界定者具有相同涵義。 * 僅供識別 1 普通決議案 1. 「動議： 2 (a) 謹此批准及採納本公司二零二五年H股激勵計劃的計劃規則（註有 「A」字樣的文本已送呈本次大會，並由大會主席簡簽以資識別），並 授權董事(i)根據計劃規則授出股份獎勵；(ii)不 ...

此乃要件 請即處理 閣下如對本通函的任何方面或應採取的行動有任何疑問，應諮詢 閣下的持牌證券商、 銀行經理、律師、專業會計師或其他專業顧問。 閣下如已將名下全部山東威高集團醫用高分子製品股份有限公司的股份售出或轉讓， 應立即將本通函及隨附的代表委任表格交予買方或承讓人，或送交經手買賣或轉讓的銀 行、持牌證券商或其他代理商，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） (1)建議採納二零二五年H股激勵計劃 (2)建議修訂公司章程 (3)建議中期股息 (4)建議重新委任董事 及 (5)股東特別大會通告 本公司謹訂於二零二五年十月十七日（星期五）上午九時正假座中華人民共和國（「中國」） 山東省威海火炬高技術產業開 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 更改股東特別大會日期、 更改暫停辦理股份過戶登記手續期間及記錄日期 茲提述山東威高集團醫用高分子製品股份有限公司（「本公司」）日期為二零 二五年八月二十七日之截至二零二五年六月三十日止六個月之中期業績公佈 （「該公佈」），內容有關（其中包括）本公司股東特別大會（「股東特別大會」）日 期及暫停辦理股份過戶登記手續期間以釐定出席股東特別大會並於會上投票 的權利。除文義另有所指外，本公佈所用詞彙與該公佈所界定者具有相同涵 義。 更改股東特別大會日期 董事會宣佈，原定於二零二五年十月十六日（星期四）舉行之股東特別大會（載 於該公佈）將改期至二零二五年十月十七日（星期五）舉行（「改期股東特別大 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [5][20]. Core Insights - The company's revenue for the first half of 2025 remained stable at 6.644 billion, with a year-on-year decline in net profit attributable to shareholders of 9.0% [1][7]. - The medical device segment showed stable pricing, while the pharmaceutical packaging segment saw a significant increase in overseas sales, with the "ship-to-ship" sales ratio rising to 35%, an increase of nearly 10 percentage points year-on-year [2][10]. - The company has established a multi-dimensional barrier with brand image, quality control, scale effect, and cost advantages, indicating strong growth potential and industry leadership [20]. Revenue and Profitability - The company's revenue for the first half of 2025 was 66.44 billion (+0.1%), while the net profit attributable to shareholders was 10.08 billion (-9.0%), with a 12.7% decline after excluding one-time impacts [1][7]. - The gross profit margin decreased to 49.7% (down 1.2 percentage points year-on-year), reflecting pricing pressures on products [3][14]. - The net profit margin fell to 15.9% (down 1.5 percentage points year-on-year) [3][14]. Segment Performance - The medical device business generated approximately 33.0 billion in revenue, remaining stable year-on-year, but the segment profit decreased by 17.1% due to price declines and foreign exchange losses [2][10]. - The orthopedic business revenue was 7.3 billion (-1.6%), primarily due to a change in sales model for joint products, leading to lower factory prices [11]. - The interventional business revenue was 9.9 billion (-2%), with growth in the U.S., Europe, Middle East, and Africa regions [11]. Financial Forecasts - The revenue forecasts for 2025-2027 are adjusted to 137.6 billion, 148.5 billion, and 159.6 billion, with year-on-year growth rates of 5.1%, 8.0%, and 7.4% respectively [20]. - The net profit forecasts for the same period are 21.2 billion, 24.0 billion, and 26.8 billion, with year-on-year growth rates of 2.3%, 13.4%, and 11.6% respectively [20]. Cash Flow and Dividends - The operating cash flow for the first half of 2025 was 8.82 billion, with a cash content of net profit reaching 87%, indicating a healthy cash flow position [18]. - The board proposed a dividend of 4.42 billion for the first half of the year, maintaining a 50% payout ratio based on operating net profit [1][7].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][20]. Core Insights - The company's revenue for the first half of 2025 remained stable at 6.644 billion, with a year-on-year decline in net profit attributable to shareholders of 9.0% [1][7]. - The board proposed a dividend of 442 million, maintaining a 50% payout ratio based on operational net profit [1][7]. - The medical device segment showed stable pricing, while the pharmaceutical packaging segment saw a significant increase in overseas sales, with "ship-to-ship" sales accounting for 35% of total sales, up nearly 10 percentage points year-on-year [2][10]. - The company has established a multi-dimensional barrier with brand image, quality control, scale effect, and cost advantages, indicating strong growth potential and industry leadership [20]. Revenue and Profitability - In the first half of 2025, the medical device business generated approximately 3.3 billion in revenue, with a year-on-year decline in segment profit of 17.1% due to price reductions and foreign exchange losses [2][10]. - The orthopedic business revenue was 730 million, down 1.6%, primarily due to a change in sales model affecting joint product pricing [11]. - The overall gross profit margin for the company was 49.7%, a decrease of 1.2 percentage points year-on-year, while the net profit margin fell to 15.9% [3][14]. Financial Forecasts - The revenue forecasts for 2025-2027 are adjusted to 137.6 billion, 148.5 billion, and 159.6 billion, with year-on-year growth rates of 5.1%, 8.0%, and 7.4% respectively [20]. - The net profit attributable to shareholders is projected to be 21.2 billion, 24.0 billion, and 26.8 billion for the same period, with growth rates of 2.3%, 13.4%, and 11.6% [20]. - The current price-to-earnings ratio is estimated at 11x for 2025, 10x for 2026, and 9x for 2027 [20].

Core Viewpoint - Weigao Group (01066) announced that its board has approved the proposal for the full circulation of 48.3 million unlisted shares held by certain shareholders, which represents approximately 1.06% of the total issued shares as of the announcement date [1] Summary by Relevant Sections - **Shareholder Approval** The board of Weigao Group has reviewed and approved the proposal regarding the conversion of 48.3 million unlisted shares into H-shares, pending all necessary approvals [1] - **Regulatory Compliance** The conversion of the 48.3 million unlisted shares into H-shares will occur after obtaining all relevant approvals, including the filing notice from the China Securities Regulatory Commission and approval from the Stock Exchange of Hong Kong, while adhering to all applicable laws, rules, and regulations [1] - **Listing Application** The company will apply to the Stock Exchange of Hong Kong for the listing and trading of the H-shares on the main board [1]

智通财经APP讯，威高股份(01066)发布公告，董事会已审议并批准有关若干股东持有的4830万股未上市 股份(相当于本公布日期已发行股份总数约1.06%)之建议H股全流通。于获得所有相关批准(包括中国证 监会发出的备案通知及联交所的批准)并遵守所有适用法律、规则及法规后，有关4830万股未上市股份 将转换为H股。本公司将向联交所申请有关H股于联交所主板上市及买卖。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） (1)建議修訂公司章程 及 (2)建議實行H股全流通 本公佈乃由本公司根據上市規則第13.09(2)(a)條及第13.51(1)條及證券及期貨 條例（香港法例第571章）第XIVA部內幕消息條文（定義見上市規則）作出。 建議修訂公司章程 董事會建議修訂公司章程，以（其中包括）(i)令現有公司章程符合自二零二四 年七月一日起生效的公司法及中國證監會於二零二五年三月二十八日發佈的 《上市公司章程指引》等相關法律、法規、規章和規範性文件的規定；(ii)鑒於 二零二四年六月十一日生效的有關庫存股份的上市規則修訂，令本公司可靈 活購買或收購股份作為庫存股份持有；(iii)配合近期上市規則有關進 ...

威高股份(01066)发布公告，燕霞因个人发展需求，已提出辞任公司董事会副主席及非执行董事，自 2025年10月8日起生效。辞任生效后，燕霞将不再担任公司任何职务。 ...

智通财经APP讯，威高股份(01066)发布公告，燕霞因个人发展需求，已提出辞任公司董事会副主席及非 执行董事，自2025年10月8日起生效。辞任生效后，燕霞将不再担任公司任何职务。 ...